New CLL strategy: add immune therapy only when needed
NCT ID NCT05650723
First seen Mar 07, 2026 · Last updated Apr 28, 2026 · Updated 7 times
Summary
This study tests a personalized approach for people with CLL, a type of blood cancer. Instead of giving everyone three drugs from the start, patients first receive two oral medications (zanubrutinib and venetoclax). Only those who still have signs of cancer after that get an additional immune therapy (obinutuzumab). The goal is to reduce side effects and overtreatment while still effectively controlling the disease. About 50 adults with CLL will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine/NewYork-Presberteryian Hospital
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.